HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (15) Citing Articles via Google Scholar Google Scholar Articles by Ramsdell, J. W. Articles by Colice, G. L. Search for Related Content PubMed PubMed Citation Articles by Ramsdell, J. W. Articles by Colice, G. L.

Safety of Long-term Treatment With HFA Albuterol^*

^* From the Department of Medicine (Dr. Ramsdell), University of California, San Diego Medical Center, San Diego, CA; and 3M Pharmaceuticals (Ms. Klinger, Mr. Ekholm, and Dr. Colice), St. Paul, MN.

Background: Chlorofluorocarbons (CFCs) used as propellants in metered-dose inhalers deplete stratospheric ozone, which results in serious public health concerns. Albuterol has been reformulated in the non-ozone-depleting propellant, hydrofluoroalkane-134a (HFA albuterol).

Objectives: The primary objective was to compare the safety of HFA albuterol to an albuterol product formulated in chlorofluorocarbon propellants (CFC albuterol) during 1 year of treatment in asthmatics. Bronchodilator efficacy of the two products was assessed as a secondary objective.

Methods: The results from two open-label, parallel-group trials of similar design in asthmatics requiring short-acting ß-agonists for symptom control were combined. Patients took two puffs bid of either HFA albuterol or CFC albuterol for 1 year. Additional puffs of study drug were allowed as needed to control asthma symptoms. Adverse events were recorded at clinic visits. Patients self-administered study drug at quarterly visits and underwent serial spirometry during a 6-h period postdose. Bronchodilator efficacy variables, based on FEV₁ response to study drug, were proportion of responders, time to onset of effect, peak percent change, time to peak effect, duration of effect, and area under the curve. Differences between products and changes over time in efficacy variables were assessed using an analysis of variance model. Regression analyses with FEV₁ as a covariate were performed post-hoc to analyze changes in bronchodilator efficacy over time.

Results: Demographic and baseline characteristics were similar for patients receiving HFA albuterol (n = 337) and CFC albuterol (n = 132). Total reported adverse events were similar for the two treatments. Differences in only four individual adverse events were noted: the HFA albuterol group reported more gastroenteritis and dizziness; the CFC albuterol group reported more epistaxis and expectoration. Adverse events attributed to study drug use were infrequent. No serious adverse events were related to study drug use. Predose FEV₁ at quarterly visits increased to a small extent in both groups from month 0 to month 12. The bronchodilator efficacy of HFA albuterol was comparable to that of CFC albuterol at the quarterly visits, but decreased from baseline for both products over the 12 months of treatment. Use of inhaled corticosteroids, nasal corticosteroids, or theophylline did not explain the increase in predose FEV₁ over time and did not protect patients from developing reduced bronchodilator efficacy by month 12. The change in predose FEV₁ did not entirely account for the reduced bronchodilator efficacy over time.

Conclusions: HFA albuterol has a safety profile similar to that of CFC albuterol during chronic, scheduled use, and both drugs are well tolerated. HFA albuterol and CFC albuterol provided comparable bronchodilator efficacy, but bronchodilator efficacy decreased for both products with 1 year of use.

Key Words: albuterol • asthma • ß-adrenergic bronchodilator • ß-agonist • HFA-134a propellant

This article has been cited by other articles:

				A. A Fisher, M. W Davis, and D. A McGill Acute Myocardial Infarction Associated with Albuterol Ann. Pharmacother., December 1, 2004; 38(12): 2045 - 2049. [Abstract] [Full Text] [PDF]

				J Wright, D Brocklebank, and F Ram Inhaler devices for the treatment of asthma and chronic obstructive airways disease (COPD) Qual. Saf. Health Care, January 12, 2002; 11(4): 376 - 382. [Abstract] [Full Text] [PDF]

				F. S F Ram, J. Wright, D. Brocklebank, and J. E S White Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering beta 2 agonists bronchodilators in asthma BMJ, October 20, 2001; 323(7318): 901 - 901. [Abstract] [Full Text]